Structure–activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties-Reference-Cited by-同舟云学术

Structure–activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties

Published:2008-05 Issue:9 Volume:18 Page:2845-2849
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Corte James R.,Fang Tianan,Pinto Donald J.P.,Han Wei,Hu Zilun,Jiang Xiang-Jun,Li Yun-Long,Gauuan Jolicia F.,Hadden Mark,Orton Darren,Rendina Alan R.,Luettgen Joseph M.,Wong Pancras C.,He Kan,Morin Paul E.,Chang Chong-Hwan,Cheney Daniel L.,Knabb Robert M.,Wexler Ruth R.,Lam Patrick Y.S.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference30 articles.

1. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin

2. Interaction of Warfarin With Drugs, Natural Substances, and Foods

3. Serine proteases as targets for antithrombotic therapy

4. Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cribado virtual y análisis de complejos enzima-ligando para el factor Xa (FXa) en la cascada de la coagulación humana;Bionatura;2023-12-15

2. Synthesis and Selected Transformations of New 2‐Aminopyridine Derivatives Based on Furan‐2(5H)‐ones;ChemistrySelect;2023-08-09

3. Discovery and development of Factor Xa inhibitors (2015–2022);Frontiers in Pharmacology;2023-02-21

4. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema;Journal of Medicinal Chemistry;2022-10-17

5. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema;J MED CHEM;2022